Danni Yu
Danni Yu
Eli Lilly and Company, Nektar Therapeutics
Verified email at nektar.com
Title
Cited by
Cited by
Year
A Coastal Cline in Sodium Accumulation in Arabidopsis thaliana Is Driven by Natural Variation of the Sodium Transporter AtHKT1;1
I Baxter, JN Brazelton, D Yu, YS Huang, B Lahner, E Yakubova, Y Li, ...
PLoS genetics 6 (11), e1001193, 2010
3472010
Shrinkage estimation of dispersion in Negative Binomial models for RNA-seq experiments with small sample size
D Yu, W Huber, O Vitek
Bioinformatics 29 (10), 1275-1282, 2013
1002013
miR-191 and miR-135 are required for long-lasting spine remodelling associated with synaptic long-term depression
Z Hu, D Yu, Q Gu, Y Yang, K Tu, J Zhu, Z Li
Nature communications 5 (1), 1-17, 2014
832014
Expression of miRNAs and their cooperative regulation of the pathophysiology in traumatic brain injury
Z Hu, D Yu, C Almeida-Suhett, K Tu, AM Marini, L Eiden, MF Braga, J Zhu, ...
PloS one 7 (6), e39357, 2012
792012
miR-26a and miR-384-5p are required for LTP maintenance and spine enlargement
QH Gu, D Yu, Z Hu, X Liu, Y Yang, Y Luo, J Zhu, Z Li
Nature communications 6 (1), 1-15, 2015
682015
High-resolution genome-wide scan of genes, gene-networks and cellular systems impacting the yeast ionome
D Yu, JMC Danku, I Baxter, S Kim, OK Vatamaniuk, O Vitek, M Ouzzani, ...
BMC genomics 13 (1), 1-25, 2012
542012
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced …
MW Saif, JA Knost, EG Chiorean, SRP Kambhampati, D Yu, B Pytowski, ...
Cancer chemotherapy and pharmacology 78 (4), 815-824, 2016
462016
A phase I study of LY3009120, a Pan-RAF inhibitor, in patients with advanced or metastatic cancer
RJ Sullivan, A Hollebecque, KT Flaherty, GI Shapiro, JR Ahnert, ...
Molecular cancer therapeutics 19 (2), 460-467, 2020
192020
Proteomic analysis of high NaCl-induced changes in abundance of nuclear proteins
J Li, JD Ferraris, D Yu, T Singh, Y Izumi, G Wang, M Gucek, MB Burg
Physiological Genomics, 2012
162012
Noise reduction in genome-wide perturbation screens using linear mixed-effect models
D Yu, J Danku, I Baxter, S Kim, OK Vatamaniuk, DE Salt, O Vitek
Bioinformatics 27 (16), 2173-2180, 2011
142011
Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study
KA Autio, CA Klebanoff, D Schaer, JSW Kauh, SF Slovin, M Adamow, ...
Clinical Cancer Research 26 (21), 5609-5620, 2020
122020
Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant …
KA Autio, CA Klebanoff, D Schaer, JS Kauh, SF Slovin, VS Blinder, ...
Journal of Clinical Oncology 37 (15_suppl), 2548-2548, 2019
102019
Statistical methods for integrating epigenomic results
SY Yoo
Purdue University, 2008
8*2008
A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.
A Dowlati, HS Rugo, RD Harvey, RR Kudchadkar, RD Carvajal, GA Manji, ...
Journal of Clinical Oncology 35 (15_suppl), 2523-2523, 2017
72017
Combining gene sequence similarity and textual information for gene function annotation in the literature
L Si, D Yu, D Kihara, Y Fang
Information retrieval 11 (5), 389-404, 2008
72008
Blocking TIM-3 in treatment-refractory advanced solid tumors: a Phase Ia/b study of LY3321367 with or without an anti-PD-L1 antibody
JJ Harding, V Moreno, YJ Bang, MH Hong, A Patnaik, J Trigo, ...
Clinical Cancer Research 27 (8), 2168-2178, 2021
62021
A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients.
DS Hong, A Hollebecque, MS Gordon, KT Flaherty, G Shapiro, J Rodon, ...
Journal of Clinical Oncology 35 (15_suppl), 2507-2507, 2017
62017
& Salt DE (2010)
I Baxter, JN Brazelton, D Yu, YS Huang, B Lahner, E Yakubova
A coastal cline in sodium accumulation in Arabidopsis thaliana is driven by …, 0
6
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial
A Patnaik, TA Yap, HC Chung, MJ de Miguel, YJ Bang, CC Lin, WC Su, ...
Clinical Cancer Research 27 (5), 1267-1277, 2021
42021
Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5).
WM Saif, JA Knost, EG Chiorean, SRP Kambhampati, D Yu, B Pytowski, ...
Journal of Clinical Oncology 33 (15_suppl), 3530-3530, 2015
42015
The system can't perform the operation now. Try again later.
Articles 1–20